Johnson et al. suggested that for grades 3 and 4 colitis patients, the addition of infliximab (targeted TNFα) to glucocorticoids was significantly associated with a shorter time to symptom resolution than utilization of glucocorticoids alone (Johnson et al., 2018). The gene discussed is TNF; the disease is colitis.